Contingency Management Is the Only Treatment for Stimulants That Actually Works. Only Five States Cover It.

There is no FDA-approved medication for methamphetamine, cocaine, or other stimulant use disorders. After two decades of trials, the most consistent and meaningful clinical outcome data in stimulant treatment comes from contingency management — a behavioral intervention that pays people, with modest gift-card-style incentives, for stimulant-free urine samples and treatment attendance.

The California Health Care Foundation calls it the first effective treatment for methamphetamine addiction. The HHS Office of the Assistant Secretary for Planning and Evaluation has published implementation guidance. SAMHSA has issued an advisory. The clinical evidence is, at this point, settled.

The coverage isn’t. As of May 2026, five state Medicaid programs have CMS-approved contingency management benefits: California (via the CalAIM 1115 waiver), Delaware, Hawaii, Montana, and Washington. Michigan and Rhode Island have applications pending. The remaining 43 states, including Arizona, do not reimburse CM under Medicaid — meaning the most evidence-based stimulant-UD intervention is largely available only in cash-pay or grant-funded settings.

California’s program is the largest dataset on what scaled CM looks like. The Recovery Incentives Program has enrolled approximately 8,500 members across 100 sites, with incentive structures running 12–24 weeks (Montana the shortest; Delaware extending up to 64 weeks for pregnant and postpartum members). Interim outcomes show higher retention in other drug treatment programs, reduced ED utilization, and a reduction in overdose deaths — the latter likely reflecting that stimulant-only users were getting connected to broader care, including naloxone distribution, that they hadn’t been touching before.

The relevant question for Arizona, where methamphetamine continues to drive a meaningful share of the rising overdose figures alongside fentanyl, is whether the AHCCCS infrastructure can support a CM filing. AHCCCS already operates under an 1115 demonstration framework; a CM benefit addition would not require building waiver infrastructure from scratch. What it would require is the political and operational will to ask CMS for it.

Cytisinicline’s June 20 PDUFA date is the news peg most addiction-pharmacology calendars are watching. But on the stimulant side, the more consequential 2026 question is whether the cohort of CM-approved states grows from five to ten. That is a Medicaid-policy story, not a drug-approval story — and Arizona has the structure to be on the list if it wants to be.

Sources: CHCF · Health Law & Policy Brief · HHS ASPE · California DHCS